LEAP-10 (NCT04199104) is a randomized phase III study comparing pembrolizumab plus lenvatinib to pembrolizumab plus placebo as first-line treatment in patients with R/M HNSCC whose tumor is associated with CPS PD-L1 score ≥ 1. Here, CD274 is linked to neoplasm.